ERBB2 and breast cancer: Luminal B cancers account for 30% of HER2-overexpressing breast cancers, thus indicating the involvement of receptor tyrosine kinase-regulated signaling pathways such as PI3K/Akt and MAPK in cell proliferation [12,13].